
Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program
RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies for severe muscle diseases, today announced the renewal of its Orphan Drug …